White Paper Authentic Recombinant Activin A and BMP- 4 Production Using HumanZyme s Proprietary Human Cell Line Expression Technology
|
|
- Robyn Glenn
- 6 years ago
- Views:
Transcription
1 White Paper Authentic Recombinant Activin A and BMP- 4 Production Using HumanZyme s Proprietary Human Cell Line Expression Technology Mark Azam, Ph.D. VP - R&D and Manufacturing Patricia Ahrweiler, Ph.D. Sr. Marketing Consultant Summary Human TGF- β superfamily cytokine expression and secretion involves multi- step posttranslational processing in vivo. The in vitro production these proteins including Activin A and BMP- 4 in non- human cell expression systems lacking this processing machinery (E. coli, SF9, CHO) often results in a mixture of precursor and mature proteins misformed disulfide bonds, and missing or incorrect glycosylation. To meet the increasing demands for recombinant human Activin A and BMP- 4 for stem cell and cell therapy research, HumanZyme has utilized their proprietary human cell (HEK293) expression system for production of HumanKine Activin A and BMP- 4 as the correct, mature, fully processed, active protein with authentic folding, glycosylation, subunit assembly, and disulfide linkages.
2 Introduction The transforming growth factor- beta (TGF- β) superfamily of cytokines are a large group of structurally- related signaling proteins that includes the activin/inhibin family, bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), the TGF- β subfamily, and the glial cell line- derived neurotrophic factor (GDNF) family. These proteins are involved in the regulation of essential cellular and developmental processes such as growth, development, tissue homeostasis and regulation of the immune system. The use of human recombinant TGF- β family proteins has Figure 1. Proteolytic Processing of TGF beta Superfamily Ligands become widespread in stem cell research, cell therapy research and clinical applications due to their important role in development and differentiation. However, the production of recombinant TGF- β proteins in sufficient quantities can be challenging, since ligand members of the TGF- β superfamily all undergo multi- step processing during maturation and secretion (Figure 1). These proteins are all synthesized as large precursors (preproproteins) with N- terminal peptides that are proteolytically cleaved in two steps to yield glycosylated carboxy- terminal mature protein homodimers. Each subunit contains 4 to 7 cysteine residues forming multiple intrasubunit disulfide bonds, and one cysteine forming a disulfide bond with the other subunit to stabilize the dimer. Since these ligands are only active as homo- or heterodimers, the correct folding, glycosylation and subunit association is critical to their biological activity. Currently, TGF- β family proteins are predominantly produced in non- human cells (E. coli, SF9, CHO) often resulting in a mixture of precursor and mature proteins, misformed disulfide bonds, and missing or incorrect glycosylation. In addition, a number of important cytokines are not commercially available at all due to expression systems with inadequate proteolytic processing, protein folding or other post- translational modifications such as correct glycosylation that do not occur in the non- human cell expression systems (Aono, Hazama et al.).
3 To meet the demands for recombinant human TGF- β family proteins, HumanZyme has utilized their human cell (HEK293) expression system with native human cellular manufacturing capabilities to produce TGF- β family proteins with correct proteolytic processing, folding, glycosylation, subunit assembly, and disulfide linkages. In this White Paper, we describe the details of production of HumanKine Activin A and BMP- 4 using our proprietary cell expression system. HumanKine Activin A Activin A belongs to the TGF- β superfamily and exhibits a wide range of biological activities including regulation of cellular proliferation and differentiation, and promotion of neuronal survival. Since Activin A has also been shown to be essential to maintaining pluripotency in in vitro stem cell culture, its use is widespread in stem cell and cell therapy research. Figure 2. HumanKine Activin A vs. CHO- expressed Activin A, like other members of the TGF- β family, is a disulfide- linked dimeric protein produced as precursor with an amino- terminal propeptide that is enzymatically cleaved to release the carboxy- terminal bioactive ligand, and as such is difficult to produce in an in vitro expression system. Essentially, the following criteria need to be met (Pangas and Woodruff): 1) Correct processing of the subunit peptides from prepropeptide to mature, biologically active peptide 2) Correct assembly of monomers into active dimers 3) Expression at sufficiently high levels for purification 4) Final products must be bioactive using established assays. In addition, the correct N- linked glycosylation of recombinant Activin A has recently been shown to be necessary for dimer assembly and secretion of the bioactive protein, so an expression system must also be capable of correct glycosylation (Antenos, Stemler et al.). The expression of Activin A in CHO cells has been reported (Pangas and Woodruff), however numerous challenges with its expression at high levels were observed including low yields, cellular toxicity, and high levels of uncleaved high molecular
4 weight precursor forms of Activin A (Pangas and Woodruff), (Papakonstantinou, Harris et al.). Expression of a fully active Activin A in E. coli is not possible, since bacterial machinery is not capable of the complex proteolytic processing or correct folding and disulfide linkages to produce active protein. Consequently, bacterial expression usually produces large quantities of the inactive mature protein into inclusion bodies, followed by solubilization and refolding processes that may or may not alter the biologic activity of the recombinant protein. Activin A is expressed from a stable cell culture of engineered human HEK293 cells into culture media as a fully active, correctly folded homodimer of kd. As shown in Figure 2, HumanKine Activin A analyzed on a SDS- PAGE gel shows Figure 3a. Lot to Lot Activity Consistency of HumanKine Activin A only the correct, mature, fully processed protein, while the CHO- expressed source shows higher molecular weight precursor protein and other contaminants. In addition, since researchers require consistency from lot to lot for long- term research studies or scale- up needs, HumanZyme has shown this proprietary expression system to be robust and stable. Figure 3a and 3b show the lot- to- lot consistency of Activin A production activity and purity, with biological activity determined by the dose- dependent inhibition of Figure 3b. Lot to Lot Consistency of HumanKine Activin A Purity proliferation of the MPC- 11 (mouse plasmocytoma) cell line (Phillips, Brauman et al. 1999) and purity determined by SDS PAGE gel electrophoresis. BMP- 4 Another member of the TGF- β family, bone morphogenetic proteins (BMPs) were originally identified as regulators of cartilage and bone formation, but have since been found to also play important roles in the morphogenesis of tissues and organs during embryonic development.
5 BMP proteins are synthesized as inactive kda prepropeptides of amino acids. Like all members of the TGF- β superfamily, a complex proteolytic path produces a mature, secreted, biologically active amino acid C- terminal peptide as a dimer stabilized by a disulfide bond. BMP proteins have 7 cysteine residues per subunit, with 6 forming intermolecular disulfide linkages and one forming a disulfide bond with the other subunit to stabilize the dimer. The peptide monomers form the characteristic cysteine knot structure consisting of six conserved cysteine residues with N- linked glycosylation. Figure Step Purification of HumanKine BMP- 4 Human recombinant BMP proteins are widely used in stem cell and cell therapy applications, and recently BMP- 2 and BMP- 7 have been approved by the FDA for certain clinical uses (Lo, Ulery et al.). Recombinant BMP- 4 is used in vitro in the differentiation of human embryonic stem cell cultures (hescs), and induced pluripotent stem cells (ipscs). Production of BMP proteins for both research and clinical use has been challenging, due to the complex proteolytic processing preceding secretion of the mature, active protein. BMP Figure 5. Activity and Purity of HumanKine BMP- 4 proteins were first expressed in CHO cells, albeit with low expression levels. Bacterial expression in E. coli produces much larger yields of protein, however typically without glycosylation. Bacterial expression also sequesters BMP- 4 protein in inclusion bodies that need to be refolded using denaturing buffers (Bessa, Casal et al.). HumanZyme has streamlined the expression and purification of BMP- 4 from a human cell line (HEK293) to produce purified, correctly processed, folded, glycosylated, and disulfide linked protein in sufficient quantities for research use (Figure 4). The active, correctly folded and disulfide linked, glycosylated monomer is expressed from the HEK293 host and is efficiently purified from the culture media in a 2- step process. The purified protein migrates at an apparent molecular
6 weight of 34 kda in non- denaturing conditions, and its activity was determined by the dose- dependent induction of alkaline phosphatase production in the ATDC- 5 (Mouse chondrogenic) cell line (Figure 5). Summary The TGF- β superfamily of proteins including Activin A and BMP- 4 undergo a complex proteolytic processing and N- linked glycosylation for correct maturation and secretion of the active protein. TGF- β family recombinant proteins have been difficult to produce commercially, due to their proteolytic multi- step processing during maturation, secretion of a dimeric disulfide- linked active form, and other problematic production issues such as cell toxicity and large precursor contamination. HumanZyme has developed a unique and robust human cell (HEK- 293) expression system for the correct and biologically active expression of TGF- β superfamily proteins, including Activin A and BMP- 4. Purification of these proteins has been simplified to isolate the correct dimer from culture media. References Antenos, M., M. Stemler, I. Boime and T. K. Woodruff (2007). "N- linked oligosaccharides direct the differential assembly and secretion of inhibin alpha- and betaa- subunit dimers." Mol Endocrinol 21(7): Aono, A., M. Hazama, K. Notoya, S. Taketomi, H. Yamasaki, R. Tsukuda, S. Sasaki and Y. Fujisawa (1995). "Potent ectopic bone- inducing activity of bone morphogenetic protein- 4/7 heterodimer." Biochem Biophys Res Commun 210(3): Bessa, P. C., M. Casal and R. L. Reis (2008). "Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts)." J Tissue Eng Regen Med 2(1): Lo, K. W., B. D. Ulery, K. M. Ashe and C. T. Laurencin (2012). "Studies of bone morphogenetic protein- based surgical repair." Adv Drug Deliv Rev 64(12): Pangas, S. A. and T. K. Woodruff (2002). "Production and purification of recombinant human inhibin and activin." J Endocrinol 172(1): Papakonstantinou, T., S. J. Harris, D. Fredericks, C. Harrison, E. M. Wallace and M. T. Hearn (2009). "Synthesis, purification and bioactivity of recombinant human activin A expressed in the yeast Pichia pastoris." Protein Expr Purif 64(2): Phillips, D. J., J. N. Brauman, A. J. Mason, D. M. de Kretser and M. P. Hedger (1999). "A sensitive and specific in vitro bioassay for activin using a mouse plasmacytoma cell line, MPC- 11." J Endocrinol 162(1):
Chaperone Co-expression Strategies for Soluble Protein Production in E. coli
Chaperone Co-expression Strategies for Soluble Protein Production in E. coli Bo Wu, Ph.D. Bo.Wu@genscript.com Table of Contents 1 2 3 4 5 6 E. Coli Expression Overview Inclusion Bodies & Refolding Expression
More informationAPA105Hu01 100µg Active Nerve Growth Factor (NGF) Organism Species: Homo sapiens (Human) Instruction manual
APA105Hu01 100µg Active Nerve Growth Factor (NGF) Organism Species: Homo sapiens (Human) Instruction manual FOR RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES [ PROPERTIES ] 1th Edition
More informationReproductive Biology and Endocrinology BioMed Central Review Smad signalling in the ovary Noora Kaivo-oja, Luke A Jeffery, Olli Ritvos and David G Mot
Reproductive Biology and Endocrinology BioMed Central Review Smad signalling in the ovary Noora Kaivo-oja, Luke A Jeffery, Olli Ritvos and David G Mottershead* Open Access Address: Programme for Developmental
More informationInhibin B (Human/Mouse/Rat) ELISA Kit
Inhibin B (Human/Mouse/Rat) ELISA Kit Catalog Number KA1683 96 assays Version: 06 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationBiochemistry Proteins
MIT Department of Biology 7.014 Introductory Biology, Spring 2005 Recitation Section 3 February 9-10, 2005 A. CBS proteins, 3D representation Biochemistry Proteins The protein we will consider today and
More informationLONG R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications
Page 1 of 5 Page 1 of 5 Return to Web Version LONG R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications By: Jennifer Fries, BioFiles 2009, 4.5, 14. LONG R 3 IGF-I is a recombinant
More informationProtein Sources (Heterologous expression of proteins)
Protein Sources (Heterologous expression of proteins) Adrian Suarez Covarrubias Before starting out - why? what? when? where? Recombinant expression? if so, choice of host: prokaryote? eukaryote? modification
More informationGrowth factor delivery
Growth factor delivery S. Swaminathan Director Centre for Nanotechnology & Advanced Biomaterials School of Chemical & Biotechnology SASTRA University Thanjavur 613 401 Tamil Nadu Joint Initiative of IITs
More informationfor SCI: Challenges for Entry and Execution of Phase 1 Clinical Trials Challenges and Opportunities of Cellular Therapeutic Development
Case Study: Human Embryonic Stem Cell Based Therapy for SCI: Challenges for Entry and Execution of Phase 1 Clinical Trials Jane S Lebkowski Ph.D NHLBI-PACT Workshop Sept 15, 2011 Challenges and Opportunities
More informationStrep-Spin Protein Miniprep Kit Catalog No. P2004, P2005
INSTRUCTION MANUAL Strep-Spin Protein Miniprep Kit Catalog No. P2004, P2005 Highlights Fast protocol to purify Strep-tagged proteins from cell-free extracts Screen your recombinant colonies directly for
More informationStrep-Spin Protein Miniprep Kit Catalog No. P2004 & P2005
INSTRUCTION MANUAL Strep-Spin Protein Miniprep Kit Catalog No. P2004 & P2005 Highlights Fast & Simple: Purify Strep-tagged proteins from cell-free extracts using a spin-column in 7 minutes High-Quality:
More informationA Hollow Fiber Bioreactor Allows Any Lab to Efficiently Express Recombinant Proteins in Mammalian Cells
A Hollow Fiber Bioreactor Allows Any Lab to Efficiently Express Recombinant Proteins in Mammalian Cells John J S Cadwell, President and CEO, FiberCell Systems Inc. Cultured mammalian cells have become
More informationHosts for Biosimilars Production: What is the future?
Hosts for Biosimilars Production: What is the future? Lloyd Ruddock, Scientific Director, Paras Biopharmaceuticals Finland 2004 2008 Company executives meet and decide 10 year roadmap Biosimilars capabilities
More informationIntegrated Protein Services
Integrated Protein Services Customer-specific protein expression, purification and analysis - - Last date of revision December 2015 Version DC04-0014 www.iba-lifesciences.com Please fill out the following
More informationStem Cells, Regenerative Medicine and cgmp (GTP)
Stem Cells, Regenerative Medicine and cgmp (GTP) Encompass Stem cell based therapies activities Collection source Purification Isolation from other cell types if needed Manipulation Minimal vs Moderate
More informationRegenerative Medicine and Stem Cell Therapies
Regenerative Medicine and Stem Cell Therapies Regenerative Medicine Major component of successful regenerated / tissue engineered organs Scaffolds A critical element is the binding of the repopulating
More informationANNOUNCEMENTS. HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134)
ANNOUNCEMENTS HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134) Lectures 6 8 Outline Stem Cell Division - symmetric - asymmetric Stem cell lineage potential - pluripotent
More informationINTEGRATED PROTEIN SERVICES
iba INTEGRATED PROTEIN SERVICES Customer-specific protein expression, purification and analysis Please fill out the following and fax to Europe +49 (0) 551-50672-181 US 1-888-531-6813 Or send the scanned
More informationSUMOstar Gene Fusion Technology
Gene Fusion Technology NEW METHODS FOR ENHANCING FUNCTIONAL PROTEIN EXPRESSION AND PURIFICATION IN INSECT CELLS White Paper June 2007 LifeSensors Inc. 271 Great Valley Parkway Malvern, PA 19355 www.lifesensors.com
More informationRnDSy-lu-2945 Recombinant Proteins
RnDSy-lu-2945 Recombinant Proteins Setting the Standard in Proteins for Over 30 Years All of our proteins are produced by scientists for scientists, so we understand that producing recombinant proteins
More informationOverview of Biosimilars: How Do They Differ From Generics? Thomas Felix, MD R&D Policy Global Regulatory Affairs and Safety
Overview of Biosimilars: How Do They Differ From Generics? Thomas Felix, MD R&D Policy Global Regulatory Affairs and Safety 1 Our Dual Role Amgen is a biotechnology company developing both innovative biologic
More informationPRIME-XV Cell Therapy Products by
PRIME-XV Cell Therapy Products by Product List 2017 TRINOVA BIOCHEM now distributes the PRIME-XV Cell Therapy line by Irvine Scientific in Germany, Austria and Switzerland. Irvine Scientific is a worldwide
More informationhpsc Growth Medium DXF Dr. Lorna Whyte
hpsc Growth Medium DXF Dr. Lorna Whyte 27.06.2014 Training from Heidelberg Overview Background: Stem Cells Introduction: Human Pluripotent Stem Cells (hpsc) vs. Adult Stem Cells Promise of PSC Research
More informationThe United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts
The United States Pharmacopeia Strategy on Biotherapeutic Products Standards Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts U.S. Pharmacopeia Who We Are Scientific, independent, volunteer-driven,
More informationCartilage TE: from in vitro and in vivo models to the clinic. Module 3, Lecture 6!! Spring 2014!
Cartilage TE: from in vitro and in vivo models to the clinic Module 3, Lecture 6!! 20.109 Spring 2014! Lecture 5 review What are some advantages of ELISA as a protein assay?! Compare qpcr and end-point
More informationGuide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia
Guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins European Pharmacopoeia European Directorate for the Quality of Medicines & HealthCare Edition Council of Europe,
More informationModule 1 overview PRESIDENTʼS DAY
1 Module 1 overview lecture lab 1. Introduction to the module 1. Start-up protein eng. 2. Rational protein design 2. Site-directed mutagenesis 3. Fluorescence and sensors 3. DA amplification PRESIDETʼS
More informationTissue Engineered Medical Products
WORKSHOP 8 Tissue Organizer: Jeremy J. Rawlinson PhD Speakers: Jack E. Lemons, PhD Lawrence J. Bonassar, PhD Mauro R. Alini, PhD Michael J. Yaszemski, MD, PhD Standards for Tissue J. Lemons, University
More informationCase 7 A Storage Protein From Seeds of Brassica nigra is a Serine Protease Inhibitor
Case 7 A Storage Protein From Seeds of Brassica nigra is a Serine Protease Inhibitor Focus concept Purification of a novel seed storage protein allows sequence analysis and determination of the protein
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationPreclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015
Preclinical Development Drugs Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Product Development: Development process: File Approval Drug Discovery Preclinical Phase 1 Phase 2 Phase 3 Lifecycle
More informationNEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY:
NEXT GENERATION ECM-BASED ALLOGRAFT TECHNOLOGY: Potent biological scaffolds strategically control stem cell fate and function, allowing our allografts to harness the regenerative potential of patient s
More informationMid-term review. Recitation5 03/31/2014. Stem Cell Biology and Function W4193 1
Mid-term review Recitation5 03/31/2014 Stem Cell Biology and Function W4193 1 What to expect in the midterm2 It will be all so far but mainly whatever was NOT covered by the previous mid-term- not a huge
More informationRenaturation Basic Kit for Proteins
Renaturation Basic Kit for Proteins Product Number 96827 Store at 2-8 C Application The Renaturation Basic Kit for Proteins is a rapid empirical screening method used to determine the best conditions for
More informationRegulating Bone Growth and Development with Bone Morphogenetic Proteins
Regulating Bone Growth and Development with Bone Morphogenetic Proteins PHOEBE S. LEBOY Department of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6030,
More informationProtein Structure/Function Relationships
Protein Structure/Function Relationships W. M. Grogan, Ph.D. OBJECTIVES 1. Describe and cite examples of fibrous and globular proteins. 2. Describe typical tertiary structural motifs found in proteins.
More informationProtein isotopic enrichment for NMR studies
Protein isotopic enrichment for NMR studies Protein NMR studies ARTGKYVDES sequence structure Structure of protein- ligand, protein-protein complexes Binding of molecules (perturbation mapping) Dynamic
More informationRefolding the HCV E2 glycoprotein to enhance immunogenicity
Refolding the HCV E2 glycoprotein to enhance immunogenicity Lilian Phu, Rob Center, Pantelis Poumbourious, Heidi Drummer Viral Entry and Vaccines Laboratory 1 E2 glycoprotein E2 RBD Mediates viral entry
More informationXfect Protein Transfection Reagent
Xfect Protein Transfection Reagent Mammalian Expression Systems Rapid, high-efficiency, low-toxicity protein transfection Transfect a large amount of active protein Virtually no cytotoxicity, unlike lipofection
More informationCase 7 A Storage Protein From Seeds of Brassica nigra is a Serine Protease Inhibitor Last modified 29 September 2005
Case 7 A Storage Protein From Seeds of Brassica nigra is a Serine Protease Inhibitor Last modified 9 September 005 Focus concept Purification of a novel seed storage protein allows sequence analysis and
More informationContents. The Right Surface for Every Cell Extracellular Matrices and Biologically Coated Surfaces ECM Mimetic and Advanced Surfaces...
Contents The Right Surface for Every Cell... 1 Extracellular Matrices and Biologically Coated Surfaces... 2 Corning Matrigel Matrix... 2 Corning BioCoat Cultureware... 3 ECM Mimetic and Advanced Surfaces...
More informationFig. 1. A schematic illustration of pipeline from gene to drug : integration of virtual and real experiments.
1 Integration of Structure-Based Drug Design and SPR Biosensor Technology in Discovery of New Lead Compounds Alexis S. Ivanov Institute of Biomedical Chemistry RAMS, 10, Pogodinskaya str., Moscow, 119121,
More informationFusion Antibodies. Genes to Proteins to Antibodies
Fusion Antibodies Genes to Proteins to Antibodies Why Fusion Antibodies? 12 years experience of Antibody drug development Milestoned Payments European based limited company High Quality outcomes for the
More informationStem cells and tissue engineering
Stem cells and tissue engineering S. Swaminathan Director Centre for Nanotechnology & Advanced Biomaterials School of Chemical & Biotechnology SASTRA University Thanjavur 613 401 Tamil Nadu Joint Initiative
More informationEngineering of TIMP 3 as a LAP fusion protein for targeting to sites of inflammation
Received: 3 August 2018 Revised: 16 October 2018 Accepted: 17 October 2018 DOI: 10.1111/jcmm.14019 SHORT COMMUNICATION Engineering of TIMP 3 as a LAP fusion protein for targeting to sites of inflammation
More informationHis-Spin Protein Miniprep
INSTRUCTIONS His-Spin Protein Miniprep Catalog No. P2001 (10 purifications) and P2002 (50 purifications). Highlights Fast 5 minute protocol to purify His-tagged proteins from cell-free extracts Screen
More informationBasic protein and peptide science for proteomics. Henrik Johansson
Basic protein and peptide science for proteomics Henrik Johansson Proteins are the main actors in the cell Membranes Transport and storage Chemical factories DNA Building proteins Structure Proteins mediate
More informationPorcine IL-12/IL-23 p40 ELISA kit
Porcine IL-12/IL-23 p40 ELISA kit Catalog number: NB-E50014 (96 wells) The kit is designed to quantitatively detect the levels of Porcine IL-12/IL-23 p40 in cell culture supernatants. FOR RESEARCH USE
More informationDiscovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A
Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A Contacts: Marty Simonetti martysimonetti@gmail.com Kirby Alton kirby.alton@abeomecorp.com Rick Shimkets
More informationRecombinant protein production in Eukaryotic cells. Dr. W. McLaughlin BC35C
Recombinant protein production in Eukaryotic cells Dr. W. McLaughlin BC35C Recombinant protein production in Eukaryotic cells! rhuman protein must be identical to the natural protein! Prokaryotes are generally
More informationRefold SK Protein Refolding Kit
Refold SK Protein Refolding Kit 2.5mg SK v5. 2 Table of Contents Introduction...4 Kit Content...5 Instruction for Use...6 Troubleshooting Guide...9 Application Notes...16 Introduction Overexpression of
More informationCell-penetrating peptides: news for dated cellular Trojan horses
Technical Journal Club Cell-penetrating peptides: news for dated cellular Trojan horses Assunta Senatore August 5 th 2014 Overview Cell-penetrating peptides: classes and mechanisms of cell entry Overview
More informationUpdate 2015/16. Protein Expression PURIFICATION & ANALYSIS
Update 2015/16 Expression PURIFICATION & ANALYSIS OVERVIEW Expression & Purification expression can be a very complex, multi-factorial process. Each protein requires a specific intracellular environment
More informationSupplementary Information
Supplementary Information Peroxiredoxin-2 and STAT3 form a redox relay for H 2 O 2 signaling Mirko C. Sobotta 1, Willy Liou 1, Sarah Stöcker 1, Deepti Talwar 1, Michael Oehler 1, Thomas Ruppert 2, Annette
More informationSupplementary Information
Supplementary Information Disulfide-Bond Scanning Reveals Assembly State and β-strand Tilt Angle of PFO β-barrel Takehiro K. Sato, Rodney K. Tweten, and Arthur E. Johnson Supplementary Results Supplementary
More informationSeparation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3
Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3 Application Note BioPharma Authors Phu T Duong and James Martosella Agilent Technologies, Inc. 285 Centerville Rd, Wilmington,
More informationUnderstanding brain diseases from stem cells to clinical trials
Understanding brain diseases from stem cells to clinical trials Alan Mackay Sim Griffith Institute for Drug Discovery Griffith University Brisbane, QLD Making ES cells Fertilise an egg Put in a dish Embryonic
More informationDeveloping Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013
Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells
More informationXeno-Free Systems for hesc & hipsc. Facilitating the shift from Stem Cell Research to Clinical Applications
Xeno-Free Systems for hesc & hipsc Facilitating the shift from Stem Cell Research to Clinical Applications NutriStem Defined, xeno-free (XF), serum-free media (SFM) specially formulated for growth and
More informationPost-translational modification
Protein expression Western blotting, is a widely used and accepted technique to detect levels of protein expression in a cell or tissue extract. This technique measures protein levels in a biological sample
More informationHowever, only a fraction of these genes are transcribed in an individual cell at any given time.
All cells in an organism contain the same set of genes. However, only a fraction of these genes are transcribed in an individual cell at any given time. It is the pattern of gene expression that determines
More informationTranslation BIT 220 Chapter 13
Translation BIT 220 Chapter 13 Making protein from mrna Most genes encode for proteins -some make RNA as end product Proteins -Monomer Amino Acid 20 amino acids -peptides -polypeptides -Structure of Amino
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationChemical Biology In-class discussion: Tethering
In-class discussion: Tethering This discussion will focus on various Tethering Methods described by workers at Sunesis (for a review, see Erlanson et al. Ann. Rev. Biophys. Biomol. Str. 2004). Regarding
More informationExpression of the Cytokine IL-7 in E. coli and Pichia pastoris for the Identification of IL-7 Mutants that Modulate T-Cell Signaling
Expression of the Cytokine IL-7 in E. coli and Pichia pastoris for the Identification of IL-7 Mutants that Modulate T-Cell Signaling Purification Expression of USP14 and for the Development purification
More informationQA Production Material and Analytical Methods. BIT 230 Chapters 5 and 6 (Huxsoll)
QA Production Material and Analytical Methods BIT 230 Chapters 5 and 6 (Huxsoll) Material Selection Original qualification of material - vendor, specifications, safety, function, etc. Lot-to-lot testing
More informationTHE ADVANTAGE OF HOLLOW FIBER BIOREACTORS. Page 2. Page 5. Page 6. Page 4. Page 7. FiberCell Systems A BETTER WAY TO GROW CELLS
Sponsored By: FiberCell Systems A BETTER WAY TO GROW CELLS THE ADVANTAGE OF HOLLOW FIBER BIOREACTORS Page 2 Three-Dimensional (3-D) Cell Culture Page 4 Take Advantage of our Advances: A Better Way to Grow
More informationMolecular characterization, detection & quantitation of biological products Purin Charoensuksai, PhD
Molecular characterization, detection & quantitation of biological products Purin Charoensuksai, PhD Department of Biopharmacy, Faculty of Pharmacy, Silpakorn University Example of critical checkpoints
More informationDesign. Construction. Characterization
Design Construction Characterization DNA mrna (messenger) A C C transcription translation C A C protein His A T G C T A C G Plasmids replicon copy number incompatibility selection marker origin of replication
More informationIntroduction to Protein Purification
Introduction to Protein Purification 1 Day 1) Introduction to Protein Purification. Input for Purification Protocol Development - Guidelines for Protein Purification Day 2) Sample Preparation before Chromatography
More informationGSI Bovine TGF-β3 ELISA Kit-2 Plates DataSheet
Transforming growth factor, beta 3 (TGF-β3) belongs to a large family of cytokines called the Transforming growth factor beta super family (1, 2), which includes the TGF-β family, bone morphogenetic proteins
More informationInvestigation into Developmental Stages of Chicken and Quail Blood to Determine Alternative Splicing Isoforms of Myostatin
Investigation into Developmental Stages of Chicken and Quail Blood to Determine Alternative Splicing Isoforms of Myostatin Jessica Wheeler Research Thesis Advisor: Dr. Kichoon Lee Department of Animal
More informationfibrils, however, oligomeric structures and amorphous protein aggregates were
Supplementary Figure 1: Effect of equimolar EGCG on αs and Aβ aggregate formation. A D B E αs C F Figure S1: (A-C) Analysis of EGCG treated αs (1 µm) aggregation reactions by EM. A 1:1 molar ratio of EGCG
More informationSupplementary Data. In Vivo Bone Formation by impcs Materials and methods. Results. Conclusions
Supplementary Data In Vivo Bone Formation by impcs Materials and methods Induced pluripotent stem cell (ipsc)-derived mesenchymal stem cell (MSC)-like progenitor cells (impcs) (1 10 6 M-iMPC-GMs in 10
More informationGSI Rabbit TGFβ1 ELISA Kit- 2 plates DataSheet
TGFβ1 (transforming growth factor beta 1) was first identified in human platelets as a protein with a molecular mass of 25 kilodaltons with a potential role in wound healing (1). TGFB1, TGFB2, and TGFB3
More informationFGF9 monomer/dimer equilibrium regulates. extracellular matrix affinity and tissue diffusion
SUPPLEMENTARY INFORMATGION FGF9 monomer/dimer equilibrium regulates extracellular matrix affinity and tissue diffusion Masayo Harada, Hirotaka Murakami, Akihiko Okawa, Noriaki Okimoto, Shuichi Hiraoka,
More informationTITLE: Structural Characterization of the Interdomain Features of the Estrogen Receptor
AD (Leave blank) Award Number: W81XWH-07-1-0245 TITLE: Structural Characterization of the Interdomain Features of the Estrogen Receptor PRINCIPAL INVESTIGATOR: Fraydoon Rastinejad, Ph.D. CONTRACTING ORGANIZATION:
More informationBi 8 Lecture 5. Ellen Rothenberg 19 January 2016
Bi 8 Lecture 5 MORE ON HOW WE KNOW WHAT WE KNOW and intro to the protein code Ellen Rothenberg 19 January 2016 SIZE AND PURIFICATION BY SYNTHESIS: BASIS OF EARLY SEQUENCING complex mixture of aborted DNA
More informationPRIME-XV Cell Therapy Products by
PRIME-XV Cell Therapy Products by Product List 2017 TRINOVA BIOCHEM now distributes the PRIME-XV Cell Therapy line by Irvine Scientific in Germany, Austria and Switzerland. Irvine Scientific is a worldwide
More informationAntibody-Drug Conjugate Characterization and Quality Assurance
Antibody-Drug Conjugate Characterization and Quality Assurance Sarah Kennett Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA October 12, 2011 1 Disclaimer The views and
More informationNori TM Canine TGFβ2 ELISA Kit DataSheet
TGF-β2 (Transforming growth factor-beta 2) is a secreted protein known as a cytokine that performs many cellular functions and has a vital role during embryonic development (alternative names: Glioblastoma-derived
More informationHuman TGF-beta1 ELISA
K-ASSAY Human TGF-beta1 ELISA For the quantitative determination of TGF-beta1 in human cell culture supernates, serum, plasma (EDTA) and urine Cat. No. KT-1471 For Research Use Only. Not for diagnostic
More informationIntroduction to Cell/ Biomaterial Engineering
Introduction to Cell/ Biomaterial Engineering Module 3, Lecture 1! 20.109 Spring 2011! Topics for Lecture 1 Introduction to tissue engineering! motivation! basic principles + examples! Introduction to
More informationSUMO Technology For Peptides
SUMO Technology For Peptides NOVEL METHODS FOR RAPID RECOMBINANT PEPTIDE EXPRESSION AND PURIFICATION Peptides for Therapeutic, Diagnostics, Vaccines and Industrial Applications cytokinespeptidelibrarieschemokines
More informationThe Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis
The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland
More informationHeparanase Modulates Chondrogenic Factor Signaling And Is Upregulated In Ectopic Cartilage
Heparanase Modulates Chondrogenic Factor Signaling And Is Upregulated In Ectopic Cartilage Julianne Huegel, Motomi Enomoto-Iwamoto, PhD, Federica Sgariglia, Tricia Bhatti, Eiki Koyama, Maurizio Pacifici.
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationProtein Expression PURIFICATION & ANALYSIS. be INSPIRED drive DISCOVERY stay GENUINE
Expression PURIFICATION & ANALYSIS be INSPIRED drive DISCOVERY stay GENUINE OVERVIEW Expression & Purification expression can be a very complex, multi-factorial process. Each protein requires a specific
More informationNori TM Bovine TGFβ2 ELISA Kit -2 plates DataSheet
Nori TM Bovine TGFβ2 ELISA Kit -2 plates DataSheet TGF-β2 (Transforming growth factor-beta 2) is a secreted protein known as a cytokine that performs many cellular functions and has a vital role during
More informationKinetics Review. Tonight at 7 PM Phys 204 We will do two problems on the board (additional ones than in the problem sets)
Quiz 1 Kinetics Review Tonight at 7 PM Phys 204 We will do two problems on the board (additional ones than in the problem sets) I will post the problems with solutions on Toolkit for those that can t make
More informationDemonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product ICH Guidance
Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product ICH Guidance Derek Bradley M.Sc. BioClin Research Laboratories 13 th May 2016 Agenda Brief overview of biosimilars ICH
More informationUNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE MEDICINE
Massachusetts Institute of Technology Harvard Medical School Brigham and Women s Hospital VA Boston Healthcare System 2.79J/3.96J/20.441/HST522J UNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE
More informationChanges to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi
Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodies Office of Biotechnology Products Center for Drug
More informationApproaches to Nanoparticle Targeting. Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology
Approaches to Nanoparticle Targeting Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology Principles of drug targeting Drug targeting is the systemic or local administration
More informationdeltadot ANTIBODY ANALYSIS Application Note: Antibodies using LABEL FREE INTRINSIC IMAGING LONDON United Kingdom
ANTIBODY ANALYSIS using LABEL FREE INTRINSIC IMAGING Application Note: Antibodies Ana l y s i s o f Im m u n o g l o b u l i n G u s i n g deltadot s PEREGRINE I 512-p i x e l La b e l Fr e e Ca p i l
More informationINVESTIGATION OF THE BINDING SPECIFICITY OF IGF-IR USING MONOCLONAL ANTIBODIES
INVESTIGATION OF THE BINDING SPECIFICITY OF IGF-IR USING MONOCLONAL ANTIBODIES By Mehrnaz Keyhanfar, Pharm.D. A thesis submitted to the University of Adelaide, South Australia in fulfilment of the requirements
More informationChapter 9 - Protein Translation
Chapter 9 - Protein Translation Section 1: Introduction Section 2: The Genetic code! 2.1! The Problem! 2.2! The Solution Section 3: The players in Translation! 3.1! mrna! 3.2! trna! 3.3! The Ribosome Section
More informationProtein Folding in vivo. Biochemistry 530 David Baker
Protein Folding in vivo Biochemistry 530 David Baker I. Protein folding in vivo: Molecular Chaperones II. Protein unfolding in vivo: ATP driven unfolding in mitochondrial import and the proteasome. III.
More informationSupplementary Note 1. Enzymatic properties of the purified Syn BVR
Supplementary Note 1. Enzymatic properties of the purified Syn BVR The expression vector pet15b-syn bvr allowed us to routinely prepare 15 mg of electrophoretically homogenous Syn BVR from 2.5 L of TB-medium
More informationDenis V. Kurek, Sergey A. Lopatin, *Vladimir E. Tikhonov, Valery P. Varlamov
NEW AFFINITY SORBENTS FOR PURIFICATION OF RECOMBINANT PROTEINS WITH THE USE OF CHITIN-BINDING DOMAIN AS AN AFFINITY TAG Denis V. Kurek, Sergey A. Lopatin, *Vladimir E. Tikhonov, Valery P. Varlamov Centre
More information